Found: 17
Select item for more details and to access through your institution.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2022, v. 8, n. 4, p. 1, doi. 10.1177/20552173221135888
- By:
- Publication type:
- Article
Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions.
- Published in:
- Scientific Reports, 2016, p. 25920, doi. 10.1038/srep25920
- By:
- Publication type:
- Article
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5046, doi. 10.1111/dom.15811
- By:
- Publication type:
- Article
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 851, doi. 10.1111/dom.15377
- By:
- Publication type:
- Article
Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2526, doi. 10.1111/dom.15125
- By:
- Publication type:
- Article
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 656, doi. 10.1111/dom.14907
- By:
- Publication type:
- Article
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1664, doi. 10.1111/dom.14065
- By:
- Publication type:
- Article
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1369, doi. 10.1111/dom.14043
- By:
- Publication type:
- Article
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 346, doi. 10.1111/dom.13901
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 12, p. 2860, doi. 10.1111/dom.13470
- By:
- Publication type:
- Article
Patient‐reported outcomes and treatment adherence in type 2 diabetes using natural language processing: Wave 8 of the Observational International Diabetes Management Practices Study.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 9, p. 1306, doi. 10.1111/jdi.14228
- By:
- Publication type:
- Article
Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 11, p. 2309, doi. 10.1007/s13300-024-01642-2
- By:
- Publication type:
- Article
1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1-LB
- By:
- Publication type:
- Article
146-OR: Differences in HbA1c-Lowering Effect and Hypoglycemia Risk between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-146-OR
- By:
- Publication type:
- Article
1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1098-P
- By:
- Publication type:
- Article
1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1095-P
- By:
- Publication type:
- Article
1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1090-P
- By:
- Publication type:
- Article